Related Experiment Videos
Therapeutic actions of alpha-human atrial natriuretic polypeptide in 16 clinical cases
Insights
Alpha-human atrial natriuretic polypeptide (alpha-hANP) effectively lowered blood pressure and improved cardiac function in patients with hypertension and heart failure. This study highlights alpha-hANP as a promising therapeutic agent for cardiovascular disorders.
Area of Science:
- Cardiology
- Pharmacology
- Nephrology
Background:
- Essential hypertension, congestive heart failure, and cirrhosis are significant cardiovascular and renal health concerns.
- Alpha-human atrial natriuretic polypeptide (alpha-hANP) is a hormone with known vasodilatory and diuretic properties.
Purpose of the Study:
- To evaluate the safety and efficacy of synthetic alpha-hANP in human patients with essential hypertension, congestive heart failure, and cirrhosis.
- To assess the hemodynamic, renal, and hormonal effects of alpha-hANP administration.
Main Methods:
- Intravenous bolus injection of 400 micrograms of synthetic alpha-hANP in 16 patients.
- Monitoring of blood pressure, cardiac function (cardiac output, stroke volume, ejection fraction), and hemodynamic parameters.
- Measurement of urine volume, electrolytes, creatinine, and plasma levels of aldosterone, vasopressin, and noradrenaline.
Main Results:
- Rapid and potent hypotensive effect observed, particularly in hypertensive patients.
- Significant improvements in cardiac function and hemodynamics, including increased cardiac output and ejection fraction, with decreased right heart pressures.
- Increased urine volume, electrolyte, and creatinine excretion, along with alterations in plasma hormone levels. No significant adverse effects were reported.
Conclusions:
- Synthetic alpha-hANP demonstrates significant therapeutic effects in patients with hypertension and heart failure.
- Alpha-hANP shows potential as a pharmacological tool and a novel therapeutic agent for cardiovascular and renal disorders.
Abstract:
Alpha-human atrial natriuretic polypeptide (alpha-hANP) was applied to 16 clinical patients, 6 patients with essential hypertension, 7 patients with congestive heart failure and 3 patients with cirrhosis. Following intravenous bolus injection of 400 micrograms of synthetic alpha-hANP, a hypotensive effect of very rapid onset was found, which was more potent in the hypertensive patients than in the normotensive cases. Cardiac functions were improved significantly with a similar time course as the depressor response in the cases of heart failure or hypertension. Hemodynamic observations showed a marked increase in cardiac output, cardiac index, stroke volume, ejection fraction and ejection rate, and a concomitant decrease of the pressure in the right side of the heart and pulmonary circulation in these subjects. In addition, the renal response to alpha-hANP induced obvious increases in urine volume, electrolytes and creatinine excretions in all the subjects. Finally, plasma levels of aldosterone, Arg-vasopressin and noradrenaline were also altered by alpha-hANP. No significant side effects were registered. The above result confirms the therapeutic actions of alpha-hANP in human subjects and opens the possibility to research alpha-hANP as a powerful pharmacological tool as well as potential new medicine for human disorders.